IV ferric carboxymaltose vs IV iron
Number of responders ‐ mild to moderate disease (12 weeks) · IBD patients
IV ferric carboxymaltose probably leads to higher number of responders ‐ mild to moderate disease (12 weeks) compared with IV iron sucrose (moderate certainty).
1 finding from 1 review
- Interventions for treating iron deficiency anaemia in inflammatory bowel disease 2021 · Cochrane Headline outcomes onlyRR 1.25 [1.06, 1.46]1 study · 485 participantsModerate